A quarter of the money for NDI Medical's fund came from the Ohio state and the rest from undisclosed investors.

Community Health, LifePoint Hospitals, Vanguard Health Systems, Iowa Health System and Trinity Health, which in aggregate have more than 400 hospitals, will provide the $10m to corporate venturing fund, according to news provider The Tennessean.

Fluidigm will offer 5.17 million common shares when it floats on the Nasdaq stock exchange at between $13.50 and $15.50 per share.

Ligand will pay $31.2m of cash on top of the $800,000 of net cash in CyDex and a further $4.3m in 12 months time as well as undisclosed performance fees.

News provider Xconomy said angel investor Kirby Cramer was also part of the B round alongside Medtronic.

Lundbeckfond Ventures, the Denmark-based Lundbeck Foundation's life sciences investment entity known as LFI Life Science Investments until November, led the consortium investing $16m in Nexstim.

Amgen will pay $425m in cash and up to $575m in performance fees for Biovex, which is testing vaccines for cancer and genital herpes.

Former Mayo Medical Ventures and Accuitive Medical Ventures founder joins venture capital firm Linn Grove Ventures.

AcelRx will issue 6.6 million shares at up to $14 each to raise $92.9m, including 865,500 shares the investment bank Piper Jaffray can sell if demand is strong enough. After the initial public offering (IPO), AcelRx will have a market capitalisation of up to $230m based on 16.1 million shares in issuance.

Pfizer will receive an exclusive worldwide license to any therapeutic antibodies discovered under the collaboration with Theraclone eligible for undisclosed royalties and up to $632 in research funding and milestone payments.